Safety and Efficacy of AGN201781 in Neuropathic Pain

Allergan

Status and phase: Terminated; Phase 2

Conditions: Neuralgia

Treatments: Drug: AGN201781; Drug: placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00533351

201781-504

Details and patient eligibility

About

This study will explore the safety and efficacy of AGN201781 in patients with postherpetic neuralgia or post-traumatic peripheral neuralgia

Enrollment: 9 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of postherpetic neuralgia or post-traumatic peripheral neuralgia
• Moderate or severe pain associated with postherpetic neuralgia or post-traumatic peripheral neuralgia

Exclusion criteria

• Women of child-bearing potential
• Any other uncontrolled diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

9 participants in 2 patient groups, including a placebo group

AGN201781

Experimental group

Description:

AGN201781 50 mg capsules three-time daily for 2 weeks

Treatment:

Drug: AGN201781

Placebo

Placebo Comparator group

Description:

placebo 50 mg capsules three-times daily for 2 weeks

Treatment:

Drug: placebo